The Anaplastic Thyroid Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Anaplastic Thyroid Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Anaplastic Thyroid Cancer by 30 companies/universities/institutes. The top development phase for Anaplastic Thyroid Cancer is phase ii with 26 drugs in that stage. The Anaplastic Thyroid Cancer pipeline has 33 drugs in development by companies and five by universities/ institutes. Some of the companies in the Anaplastic Thyroid Cancer pipeline products market are: Novartis, AstraZeneca and University of Pisa.
The key targets in the Anaplastic Thyroid Cancer pipeline products market include Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor, and Proto Oncogene Tyrosine Protein Kinase Receptor Ret.
The key mechanisms of action in the Anaplastic Thyroid Cancer pipeline product include Programmed Cell Death Protein 1 Antagonist with six drugs in Phase II. The Anaplastic Thyroid Cancer pipeline products include nine routes of administration with the top ROA being Oral and five key molecule types in the Anaplastic Thyroid Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Anaplastic Thyroid Cancer overview
Anaplastic thyroid cancer (ATC) is a rare and aggressive form of thyroid cancer that affects mainly older people. It grows very fast and often spreads to other parts of the body, such as the lungs, bones, and brain. It causes symptoms like a large and painful neck mass, difficulty swallowing or breathing, hoarseness, and cough. The cause of ATC is unknown, but it may be related to previous radiation exposure or other thyroid cancers. ATC is hard to treat and has a poor prognosis.
For a complete picture of Anaplastic Thyroid Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
